Gibson Dunn has advised Galecto, Inc. Cooley LLP has advised the underwriters. Goodwin Procter LLP acted as intellectual property counsel for Galecto, Inc. Galecto, Inc. (Nasdaq:...
Galecto Closes $316 Million Public Offering of Common Stock
Yarrow Bioscience to Merge with VYNE Therapeutics in All-Stock Transaction
Gibson, Dunn & Crutcher LLP has advised Yarrow Bioscience. Cooley LLP has advised VYNE Therapeutics. Yarrow Bioscience and VYNE Therapeutics have entered into a definitive merger...
Galecto Acquires Damora Therapeutics and Secures $285 Million PIPE Investment
Cleary Gottlieb has advised Viking Global Investors. Gibson Dunn has advised Damora Therapeutics. The acquisition of Damora Therapeutics Inc. by Galecto Inc. was completed alongside a...
X4 Pharmaceuticals Completes $155.3 Million Public Offering of Common Stock
Gibson, Dunn & Crutcher LLP has advised X4 Pharmaceuticals, and Freshfields US LLP has advised the underwriters. Dechert LLP has served as special counsel for X4...
XOMA Royalty Corporation Establishes $50 Million At-the-Market Facility
Gibson Dunn has advised XOMA Royalty Corporation, and Duane Morris has advised H.C. Wainwright & Co., LLC. XOMA Royalty Corporation has established an at-the-market facility allowing...
XOMA Royalty Corporation Launches Common Stock Offering Worth $75 Million
Gibson Dunn & Crutcher has advised XOMA Royalty Corporation, and Duane Morris LLP has advised Leerink Partners LLC. XOMA Royalty Corporation has established two at-the-market facilities,...
Roche to Acquire 89bio in $3.5 Billion Merger Agreement
Sidley Austin has advised Roche, and Gibson, Dunn & Crutcher LLP has advised 89bio, Inc. Roche has entered into a definitive merger agreement to acquire 89bio,...
Dianthus Therapeutics Closes $288 Million Public Offering of Common Stock and Pre-Funded Warrants
Gibson Dunn and Goodwin Procter has advised Dianthus Therapeutics, Inc., while Cooley has represented the underwriters. Dianthus Therapeutics, Inc., a clinical-stage biotechnology company focused on antibody...
Arrowhead Pharmaceuticals’ Lincense Collaboration Agreement with Sarepta Therapeutics
Gibson Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, and Ropes & Gray advised Sarepta Therapeutics. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a global...
Spyre Therapeutics’ $200 Million Common Stock Offering
Gibson Dunn & Crutcher advised Spyre Therapeutics, Inc. on the offering, and Covington & Burling advised the underwriters. Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:...
89bio Inc.’s $125 Million Common Stock Offering
Gibson, Dunn & Crutcher advised 89bio, Inc. on the offering, and Cooley advised the underwriters. 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced the...
ARCA Biopharma’s Merger with Oruka Therapeutics
Wilson Sonsini Goodrich & Rosati is advising ARCA biopharma, Inc. on the transaction, while Gibson, Dunn & Crutcher is advising Oruka Therapeutics and Cooley is advising...